About us and our objectives
Founded in 1955, FIP’s Industrial Pharmacy Section (IPS) has expanded to a worldwide industrial pharmacy network. It embraces all functions where industrial pharmacists are employed.
Vision:
- A world with favourable conditions for the development of innovative, safe, effective, high quality and affordable medicines and health technologies. Ensure patient access to products and services provided by industrial pharmacists/pharmaceutical scientists, in collaboration with other pharmacists as well as other healthcare professionals.
Mission:
- To continuously embody innovation, advancement, competence and intelligence in the industrial pharmacy sector to represent and serve the pharmaceutical profession and pharmaceutical sciences within the pharmaceutical industry worldwide.
Members of the section benefit from:
- International journal Industrial Pharmacy (quarterly)
- Quarterly IPS Newsletter including information on early activities of the IPS. Upcoming events organized by IPS along with some trending information on development and manufacturing, QC/QA and the regulation of pharmaceuticals
- Reduced rates at FIP symposia and training events
- Global networking opportunities at the annual FIP congress and IPS workshops year-round, providing access to colleagues with technical, quality and regulatory expertise
- Discussion forums on current industrial topics
- Global Network aiming to provide, exchange and create scientific and technical information/guidelines that contributes for the development of Industry Pharmacists/Pharmaceutical Scientists worldwide.
- Student internships
We invite any pharmacists and scientists working in any area of the pharmaceutical industry or with the regulatory authorities to join us. Enhance and strengthen your professional life and contribute to the international community of industrial pharmacists: click here.
How we work
The current Statutes of the Industrial Pharmacy Section were adopted by the FIP Council in 2021.
The executive committee members are as follow:
|
President |
Mr Sola Solarin (Nigeria) |
|
Vice President |
Mr Didier Mouliom Ngambe (Cameroon) |
|
Treasurer |
Ms Tammy Chetty (South Africa) |
|
Secretary |
Mr Igor Linhares de Castro (Brazil) |
Contact us at fip.industrial.pharmacy@gmail.com
|
ExCo members: |
|
Ms Filipa Ferreira (Portugal) |
|
Ms Forum Gandhi (India) |
|
Mr Kaushik Desai (India) |
|
Mr Mathew Cherian (USA) |
 |
|
ExCo associates: |
|
Ms Avanthi Govender Bester (South Africa) |
|
Ms Bouchra Meddah (Morocco) |
|
Mr Chima Amadi (Nigeria and UK) |
|
Ms Ching-Yi Hsu (China Taiwan) |
|
Mr Gerard Lee See (Philippines) |
|
Mr Ibrahim El-Bagory (Saudi Arabia) |
|
Ms Maria Mantziri (Greece) |
|
Ms Sini Eskola (Belgium) |
|
Ms Tolu Taiwo (United States) |
|
Mr Yahya Choonara (South Africa) |
|
|
|
Immediate Past President: |
|
Mr Ulf Janzon (Sweden) |
|
Former Presidents: |
|
Mr Michael Anisfeld (USA) |
Follow us on social media: 
IPS Activities
Webinars
The IPS runs webinars throughout the year.
Join IPS for instant access to all past webinars.
- Harmonization and Global Efforts for Safe and Effective Generic Drugs Development (Dr. Sarah Ibrahim, Associate Director CDER, Office of Generic Drugs, FDA) 2023
- The Patient Voice in Generic Medicine Development (Dr. Sarah Ibrahim, Associate Director CDER, Office of Generic Drugs, FDA) 2022
- US Pharmacopeia: Expedited Regulatory Pathways in developing countries (Jude Nwokike, Vice President at the US Pharmacopeia) 2022
- Clinical evaluation of large volume subcutaneous injection (Wendy D Woodley, Scientist at Translational & Clinical Sciences at BD) 2022
- Generic Development and Bridging Global Regulations Description (Dr. Sarah Ibrahim, Associate Director CDER, Office of Generic Drugs, FDA) 2022
- mRNA Technology for Vaccines & Therapeutics (Michael McCaman and Seth Alexandert) 2021
- QbD in Biologics Drug Product Development and Manufacturing (Dr Krishnan Sampath) 2021
- Regulatory Considerations When Choosing Device Components in Biosimilar Dev (Alison Bascou) 2021
- Generic Dug Global Landscape- An FDA Perspective (Dr Sarah Ibrahim) 2021
- Manufacturing trends for CAR-T cell therapies (Douglas Miller) 2019
- Pharmacy in 2050. Forces That Will Shape Practice (Sola Solarin) 2017
- Sustainable Antibiotics; Antimicrobial Resistance (AMR). Pharmaceutical Industry Perspectives (Lucas Jan Wiarda) 2017
- Pharmaceutical Patents (Joanna Brougher) 2017
- Data integrity (Michael Anisfeld) 2016
- The future of the industrial pharmaceutical profession (EFPIA) 2016
- Good distribution practice audits (Petra Lehtinen, Finland) 2015
- Pharmacovigilance audit II on common findings (Susanna Heinonen, Finland) 2015
- Pharmacovigilance audits I (Susanna Heinonen, Finland) 2015
- Current issues in biotechnology (Igor Linhares de Castro, Brazil) 2014
- Fundamentals and essentials of validation (Michael Anisfeld, USA) 2014
- Current developments in drug regulation (Alan Chalmers, Switzerland) 2014
- Antibody drug conjugates (Matthew Cherian, USA) 2013
- Good distribution practices — Securing the supply chain (Michael Anisfeld, USA) 2013
- Supplier qualification goes beyond regulatory compliance (Wolfgang Löscher Filho, Brazil) 2013
- Passing a national regulatory inspection (Michael Anisfeld, USA) 2013
At the FIP congress
Topics organized by the IPS for recent FIP congresses (2014-2022) include:
- Are intellectual property rights justifiable in public health emergencies? (session)
- Industrial insights (full-day event)
- Biological drugs and gene therapy – Hot topics on regulation and policies affecting use (session)
- Breakthroughs in pharmaceutical nanotechnology for oral delivery of anticancer drugs (session)
- Research: From marketing authorization to patient use and beyond (session)
- Cell-based gene therapy – promise and challenges (session)
- Superdrugs for superbugs: Antibiotics of the future (session)
- Biosimilars for all: Research, regulation and responsible use (session)
- Individualized medicines: An ethical approach (session)
- Gene-based therapy (session)
- Supporting patients with chronic diseases (session)
- Counterfeit medicines: Safeguarding the supply chain, protecting people (session)
- Antimicrobial stewardship – Looking for global solutions (session)
- Shortages: The International Toronto Summit and beyond? (session)
- Novel regulatory approaches to accelerate access to medicines
- Can pharmacists contribute to improving patient adherence as part of pharmacovigilance?
- Improving outcomes through novel technologies – Let’s innovate together!
- Biosimilars: Understanding the issues
- Student careers
- Industrial insights — potential careers in industrial pharmacy
- Good manufacturing practice seminar
- Compounding – A core competence for the pharmacist
- Medicines for all - Impediments to achieving the goal
- Transparency and social media - Empowering the pharmacist
- Lost in translation - Preserving scientific knowledge across languages
- Do patents limit access to new medicines?
- Is there a need to harmonise the training of industrial pharmacists?
- Insights into biosimilars and non-biological complex drugs
- Improving the quality of the information pharmacist provided to patients.
- Age-related medicines
- From development to marketing
Other events
- Symposium on New Frontiers in Manufacturing Technology, Regulatory Sciences and Pharmaceutical Quality System (SINDUSFARMA / ANVISA / FIP-IPS), held annually in Brazil in June each year.
Industrial Pharmacy journal
 |
Published quarterly in association with |
Annual report
The IPS 2022 report is available here.
IPS Assembly 2023
Position of President:
Sola Solarin application and CV
Position of Secretary:
Igor Castro application and CV
Position of ExCo member:
As per IPS statutes, the ExCo positions (President, Secretary, etc) are further internally defined by the elected ExCo, so for the Assembly's election, all candidates are running for the 3 open positions at the IPS Executive Committee, whose terms end in 31 Dec 2023.
Mathew Cherian application and CV
Clement Haeck application and CV and video